Core Viewpoint - The article highlights the recent A+ round financing of Zhihong Technology, which will support the registration and market promotion of its surgical and ophthalmic microscope products, indicating strong market potential and investor confidence in the company [2][6]. Company Overview - Zhihong Technology was established in 2020, originating from a joint research platform of Tsinghua University and the PLA General Hospital, focusing on stereoscopic vision and computational microscopy [3]. - The company has developed a product line covering neurosurgery, ENT, spinal surgery, and ophthalmology, aiming to enhance visual imaging, intelligent perception, and decision-making capabilities in fine surgical scenarios [3]. Product Innovation - The company offers six models of micro-imaging and intelligent series products under its AINNOVI® brand, addressing the limitations of traditional microscopes with features like 4K resolution and real-time stereoscopic imaging [5]. - The products have received NMPA approval and CE certification, with some already deployed in over a hundred medical institutions domestically [6]. Market Trends - The global surgical microscope industry is shifting towards a fusion of "optical + digital + intelligent" technologies, with micro-vision seen as a key direction for next-generation minimally invasive surgical imaging [7]. - The transition from traditional eyepiece microscopes to direct viewing on large screens enhances operational experience and facilitates the integration of intelligent modules for navigation and information fusion [7]. Future Outlook - The article emphasizes the importance of domestic companies establishing stable advantages in core imaging, control, and intelligent processing capabilities to compete in the mid-to-high-end market [8]. - The recent financing round provides Zhihong Technology with further support for overseas expansion and product iteration, contributing to the next phase of domestic microscope replacement [8].